The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.” 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Peter J. O'Dwyer, MD
Group co-chair, ECOG-ACRIN Cancer Research Group; Professor of medicine (hematology-oncology), Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. 
By Claire Marie Porter and Paul Goldberg
Funding Opportunities

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

Project Purple, a national nonprofit dedicated to empowering the fight against pancreatic cancer, is launching the Pancreatic Cancer Research Recovery Support Grant. The initiative provides up to two years of bridge or rescue funding for promising pancreatic cancer research projects that were disrupted due to administrative funding policy changes at major federal agencies such as the NIH, the Department of Defense, or the National Science Foundation. 
Byline
Peter J. O'Dwyer, MD
Group co-chair, ECOG-ACRIN Cancer Research Group; Professor of medicine (hematology-oncology), Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account